Oritavancin has demonstrated potent activity in a study of more that 90,000 organisms tested over a 12-year period1a

MIC90 values for common ABSSSI pathogens: in vitro activity of oritavancin against gram-positive organisms from the United States and Europe (2008-2019)2


Pathogen

MIC range, (µg/mL)

MIC90, (µg/mL)

FDA breakpoint, (µg/mL)

Susceptible at breakpoint, %

MSSA (n=43,119) ≤0.008 to 0.25 0.06 0.12 99.9
MRSA (n=25,241) ≤0.008 to 0.5 0.06 0.12 99.9
S. pyogenes (n=4,868) ≤0.008 to >0.5 0.25 .025 99.9
S. agalactiae (n=4,373) ≤0.008 to >0.5 0.12 0.25 99.1
S. dysgalactiae (n=1,053) ≤0.008 to >0.5 0.25 0.25 91.8
S. anginosus group (n=1,214) ≤0.008 to 0.25 0.015 0.25 100.0
Vancomycin-susceptible E. faecalis (n=10,251) ≤0.008 to 0.5 0.03 0.12 99.8

aIn vitro activity does not necessarily correlate to clinical efficacy.

ABSSSI, acute bacterial skin and skin structure infection; FDA, US Food and Drug Administration; MIC90, minimum inhibitory concentration required to inhibit the growth of 90% of organisms; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.


See SOLO I and SOLO II phase 3 trial data

ABSSSI, acute bacterial skin and skin structure infection; MIC90, minimum inhibitory concentration required to inhibit the growth of 90% of organisms; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.

References: 1. Kimyrsa. Package insert. Melinta Therapeutics; 2021. 2. Data on file. Melinta Therapeutics.

*INDICATION AND USAGE

  • Both KIMYRSA® and ORBACTIV® are oritavancin products that are indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and methicillin-resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only).
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of oritavancin and other antibacterial drugs, oritavancin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
  • KIMYRSA® and ORBACTIV® are not approved for combination use and have differences in dose strength, duration of infusion, and preparation instructions, including reconstitution and dilution instructions and compatible diluents. Please see the full Prescribing Information for each product.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after oritavancin administration because the activated partial thromboplastin time (aPTT) test results may remain falsely elevated for approximately 120 hours (5 days) after oritavancin administration.
  • Oritavancin products are contraindicated in patients with known hypersensitivity to oritavancin.

Warnings and Precautions

  • Coagulation test interference: Oritavancin has been shown to artificially prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hours and ACT for up to 24 hours. Oritavancin has also been shown to elevate D-dimer concentrations up to 72 hours. For patients who require aPTT monitoring within 120 hours of oritavancin dosing, consider a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT.
  • Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of oritavancin products. Discontinue infusion if signs of acute hypersensitivity occur. Closely monitor patients with known hypersensitivity to glycopeptides.
  • Infusion related reactions: Infusion reactions characterized by chest pain, back pain, chills and tremor have been observed with the use of oritavancin products, including after the administration of more than one dose of oritavancin during a single course of therapy. Stopping or slowing the infusion may result in cessation of these reactions.
  • Clostridioides difficile-associated diarrhea: Evaluate patients if diarrhea occurs.
  • Concomitant warfarin use: Oritavancin has been shown to artificially prolong PT/INR for up to 12 hours. Patients should be monitored for bleeding if concomitantly receiving oritavancin products and warfarin.
  • Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.
  • Prescribing oritavancin products in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

  • The most common adverse reactions (≥3%) in patients treated with oritavancin products were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea. The adverse reactions occurring in ≥2 patients receiving KIMYRSA® were hypersensitivity, pruritus, chills and pyrexia.

Please see Full Prescribing Information for ORBACTIV®.

Please see Full Prescribing Information for KIMYRSA®.

*INDICATION AND USAGE

Both KIMYRSA® and ORBACTIV® are oritavancin products that are indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be

IMPORTANT SAFETY INFORMATION

ContraindicationsUse of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after oritavancin